Targets › FGFR4
16 programs from 15 companies in 64 trials: 40 Phase 2, 16 Phase 1, 8 Phase 3; Oncology, Gastroenterology, Other; next expected readout Nov 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid…. (UniProt, P22455)
Open in Phaseline: the race on FGFR4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TransThera Sciences (Nanjing) | TT-00420 (tinengotinib) Fibroblast growth factor receptor (FGFR) inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 3 | Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC) | Dec 2026 |
| Exelixis | Zanzalintinib (XL092) Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL | FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRA | Phase 3 | Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| Johnson & Johnson (Janssen) | Erdafitinib (TAR-210) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 3 | Urothelial Cancer; Non-Muscle Invasive Bladder Neoplasms; Urothelial Carcinoma; Advanced Malignant Solid Neoplasm … | Dec 2026 |
| Taiho Oncology | Futibatinib (TAS-120) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Advanced Cholangiocarcinoma; Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer; Advanced/Metastatic Cancer; Biliary Tract Neoplasms … | Dec 2026 |
| Shanghai Zhongshan Hospital | HRS-4642 FGFR1/2/3/4 inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Biliary Tract Cancer; Pancreatic Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Rogaratinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Locally Advanced Gastrointestinal Stromal Tumor | Jul 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Donafenib Multi-kinase inhibitor with activity against FGFRs, VEGFR, and RET | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Hepatocellular Carcinoma | Jan 2028 |
| National Cancer Center, Japan | E7090 FGFR inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 2 | Advanced or Recurrent Solid Tumors | Mar 2028 |
| Asan Medical Center | Irpagratinib FGFR4 inhibitor | FGFR4 | Phase 2 | Carcinoma, Hepatocellular | Mar 2029 |
| QED Therapeutics, a BridgeBio company | Infigratinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Achondroplasia | Mar 2030 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Derazantinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Intrahepatic Cholangiocarcinoma | – |
| Biohaven Therapeutics | Taldefgrobep Alfa FGF21 receptor agonist (FGF21 analog) | FGFR1, FGFR4, KLB | Phase 2 | Obesity | – |
| AstraZeneca | Fexagratinib (AZD4547) Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 1 | Muscle Invasive Bladder Cancer; Metastatic Breast Cancer | Nov 2026 |
| Broadenbio | BB102 FGFR4 inhibitor | FGFR4 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| National Cancer Institute (NCI) | FGFR4-CAR T Cells FGFR4-targeting chimeric antigen receptor T cell therapy | FGFR4 | Phase 1 | Rhabdomyosarcoma | Dec 2027 |
| Tyra Biosciences | TYRA-430 FGFR inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Phase 1 | Metastatic Hepatocellular Carcinoma | Jan 2028 |
Non-Muscle Invasive Bladder Neoplasms (3) Colorectal Cancer (3) Hepatocellular Carcinoma (2) Urothelial Cancer (2) Advanced Malignant Solid Neoplasm (2) Advanced Solid Tumor (2) Muscle Invasive Bladder Cancer (1) Metastatic Breast Cancer (1) Urothelial Carcinoma (1) Advanced Lymphoma (1) Malignant Solid Neoplasm (1) Bladder Cancer (1)
small molecule (10), mixed (5), antibody (1)
National Cancer Institute (NCI) (2) AstraZeneca (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Johnson & Johnson (Janssen) (1) Taiho Oncology (1) Shanghai Zhongshan Hospital (1) Exelixis (1) QED Therapeutics, a BridgeBio company (1) National Cancer Center, Japan (1) TransThera Sciences (Nanjing) (1) Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) Asan Medical Center (1) Broadenbio (1) Tyra Biosciences (1) Biohaven Therapeutics (1)
FGFR1 (13) FGFR3 (12) FGFR2 (12) MET (1) KIT (1) PDGFRA (1) KLB (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.